Evidence map›Paper›PMID 34193486›Full record

ReviewBMJ open2021

SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials.

Melanie Calvert, Madeleine King, Rebecca Mercieca-Bebber, Olalekan Aiyegbusi, Derek Kyte, Anita Slade, An-Wen Chan, E Basch, Jill Bell, Antonia Bennett and 36 more

Registry-linked trialAbstract readReview
In one paragraph

Review in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07250490 (Validation of the DIVAS-Q), which is not on this map. Cited by 68 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07250490 completednot on this mapstarted 2022, after this paper: background citation

Validation of the DIVAS-Q (Day to Day Impact of Vulvovaginal Atrophic Symptoms Questionnaire) A Portuguese Patient-Reported Outcome Measure

TypeobservationalSponsorInstituto Politécnico de LeiriaRan2022 to 2025Enrolled300ConditionsVulvovaginal Atrophy, Genital Disorder, PROMs
3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. [Extensions of guidelines for reporting types of study in medicine].Revista medica del Instituto Mexicano del Seguro Social · 2022
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Core outcome sets and trials of nutrition and metabolism interventions.Current opinion in clinical nutrition and metabolic care · 2026
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors.

Melanie CalvertCentre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK M.Calvert@bham.ac.uk.ORCID 0000-0002-1856-837X
Madeleine KingFaculty of Science, School of Psychology, University of Sydney, Sydney, New South Wales, Australia.
Rebecca Mercieca-BebberFaculty of Medicine and Health, NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-3708-9099
Olalekan AiyegbusiCentre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Derek KyteCentre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Anita SladeCentre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
An-Wen ChanWomen's College Research Institute, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
E BaschUniversity of North Carolina, Chapel Hill, North Carolina, USA.
Jill BellOncology Digital Health, AstraZeneca, Gaithersburg, Maryland, USA.
Antonia BennettCancer Outcomes Research Program, University of North Carolina, Chapel Hill, North Carolina, USA.
Vishal BhatnagarUS Food and Drug Administration, Silver Spring, Maryland, USA.
Jane BlazebyNIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK.ORCID 0000-0002-3354-3330
Andrew BottomleyDepartment of Quality of Life, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
Julia BrownClinical Trials Research Unit, University of Leeds, Leeds, UK.
Michael BrundageDepartment of Oncology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada.
Lisa CampbellMedicines and Healthcare Products Regulatory Agency, London, UK.
Joseph C CappelleriGlobal Biometrics & Data Management-Statistics, Pfizer Inc, New York City, New York, USA.
Heather DraperUniversity of Warwick, Coventry, UK.
Amylou C DueckDepartment of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona, USA.
Carolyn EllsSchool of Population and Global Health, McGill University, Montreal, Quebec, Canada.
Lori FrankPatient-Centered Outcomes Research Institute, Washington, DC, USA.
Robert M GolubJAMA, Chicago, Illinois, USA.
Ingolf GriebschBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Kirstie HaywoodWarwick Research in Nursing, University of Warwick, Warwick Medical School, Coventry, UK.
Amanda HunnIndependent Advisor, Manchester, UK.ORCID 0000-0003-2156-7279
Bellinda King-KallimanisUS Food and Drug Administration, Silver Spring, Maryland, USA.
Laura MartinDaiichi Sankyo Europe GmbH, Munchen, Germany.
Sandra MitchellNational Cancer Institute, Rockville, Maryland, USA.
Thomas MorelPatient-Centered Outcomes Research, UCB Pharma, Brussels, Belgium.
Linda NelsonValue Evidence and Outcomes-Patient Centered Outcomes, GSK, Collegeville, Pennsylvania, USA.
Josephine NorquistCenter for Observational Real-world Evidence (CORE), Patient-Centered Endpoints & Strategy, Merck & Co Inc, Kenilworth, New Jersey, USA.
Daniel O'ConnorMedicines and Healthcare Products Regulatory Agency, London, UK.
Michael PalmerCancer Research Institute, Queen's University, Kingston, Ontario, Canada.
Donald PatrickDepartment of Health Services, University of Washington, Seattle, Washington, USA.
Gary PriceCentre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Antoine RegnaultModus Outcomes, Lyon, France.
Ameeta RetzerCentre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Dennis RevickiOutcomes Research Consulting, Sarasota, Florida, USA.
Jane ScottJohnson and Johnson, Janssen Global Services LLC, High Wycombe, UK.
Richard StephensNational Cancer Research Institute Consumer Forum, London, UK.
Grace TurnerCentre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0002-9783-9413
Antonia ValakasEMD Serono Inc, Healthcare Business of Merck KGaA, Darmstadt, Germany.
Galina VelikovaLeeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
Maria von HildebrandCentre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Anita WalkerCentre for Patient Reported Outcome Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Lari WenzelUniversity of California, Irvine, California, USA.

Funding

Medical Research Council MR/K025643/1
6 · The paper itself

Abstract

Patient-reported outcomes (PROs) are used in clinical trials to provide valuable evidence on the impact of disease and treatment on patients' symptoms, function and quality of life. High-quality PRO data from trials can inform shared decision-making, regulatory and economic analyses and health policy. Recent evidence suggests the PRO content of past trial protocols was often incomplete or unclear, leading to research waste. To address this issue, international, consensus-based, PRO-specific guidelines were developed: the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)-PRO Extension. The SPIRIT-PRO Extension is a 16-item checklist which aims to improve the content and quality of aspects of clinical trial protocols relating to PRO data collection to minimise research waste, and ultimately better inform patient-centred care. This SPIRIT-PRO explanation and elaboration (E&E) paper provides information to promote understanding and facilitate uptake of the recommended checklist items, including a comprehensive protocol template. For each SPIRIT-PRO item, we provide a detailed description, one or more examples from existing trial protocols and supporting empirical evidence of the item's importance. We recommend this paper and protocol template be used alongside the SPIRIT 2013 and SPIRIT-PRO Extension paper to optimise the transparent development and review of trial protocols with PROs.

Indexed as

Quality of LifeResearch DesignChecklistHumansPatient Reported Outcome MeasuresResearch Reportclinical trialseducation & training (see medical education & training)protocols & guidelinesstatistics & research methods

Identifiers

PMID34193486
PMCPMC8246371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.